Loxo Oncology, Inc.

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Official Title: 
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Brief Summary: 
Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.
Detailed Description: 

N/A for expanded access

Available
EA Type
Individual Patients
Treatment IND/Protocol
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration

Drug: LOXO-292
Open-label expanded access

Eligibility Criteria: 

Inclusion Criteria:

- Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292

Exclusion Criteria:

- Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor

Eligibility Gender: 
All
Contacts: 

Patient Advocacy
888-406-9574
LoxoNPP@UBC.com

Patient Advocacy
855-RET-4-292 (855-738-4292)
clinicaltrials@loxooncology.com

Jen Kherani, MD
Study Director
Loxo Oncology

Loxo Oncology, Inc.
Eli Lilly and Company
EA Number: 
MeSH Terms: 
Thyroid Neoplasms, Thyroid Cancer, Papillary, Thyroid Diseases
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.